ArticleInternational journal of rheumatic diseases2026
Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3-Year J-Post-Marketing Surveillance.
Article in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioelectronic Medicine: A New Horizon for Difficult-To-Treat Rheumatoid Arthritis.International journal of rheumatic diseases · 2026Article
- Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3-Year J-Post-Marketing Surveillance.International journal of rheumatic diseases · 2026Article
- Japanese evidence on Janus kinase inhibitors for rheumatoid arthritis: a narrative review of risk-optimized use.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimThis post hoc analysis of all-case post-marketing surveillance in Japanese patients with rheumatoid arthritis assessed risk factors for major adverse cardiovascular events (MACE), malignancies, and serious infections (SI).
methodsData of patients who received tofacitinib (≥ 1 dose) were stratified by each combination of age (< 50 years and ≥ 50 years) and the number of cardiovascular (CV) risk factors (0 or ≥ 1). Incidence rates (IRs) of each adverse event (AE)-MACE, malignancies, and SI, stratified by age, CV risk factors, and patient background factors were calculated.
resultsOverall, 7021 patients were stratified by each combination of age (< 50 and ≥ 50 years) and the number of CV risk factors (0 or ≥ 1). The IRs for malignancies and SI were higher in patients aged ≥ 50 vs. < 50 years. The IRs for all AEs were higher in patients with ≥ 1 CV risk factors than 0 CV risk factors. Older age was strongly correlated with all AEs. MACE and SI were more likely to be affected by any CV risk factors, while the other AE was influenced by some of them.
conclusionsOlder age was a risk factor for all AEs (MACE, malignancies, and SI). MACE risk was also increased in patients with ≥ 1 CV risk factors versus those without. SI risk might also be increased in patients with ≥ 1 CV risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.